Do nutritional supplements have a role in age macular degeneration prevention? - PubMed (original) (raw)
Review
doi: 10.1155/2014/901686. Epub 2014 Jan 23.
Francisco Gómez-Ulla 2, Luis Arias 3, Javier Araiz 4, Ricardo Casaroli-Marano 5, Roberto Gallego-Pinazo 6, Jose J García-Medina [ 7](#full-view-affiliation-7 "University of Murcia, General University Hospital Reina Sofia, Murcia, Spain ; Ophthalmic Reseach Unit "Santiago Grisolia", Valencia, Spain."), Maria Isabel López-Gálvez 8, Lucía Manzanas 9, Anna Salas 10, Miguel Zapata 11, Manuel Diaz-Llopis 12, Alfredo García-Layana 13
Affiliations
- PMID: 24672708
- PMCID: PMC3941929
- DOI: 10.1155/2014/901686
Review
Do nutritional supplements have a role in age macular degeneration prevention?
Maria D Pinazo-Durán et al. J Ophthalmol. 2014.
Abstract
Purpose. To review the proposed pathogenic mechanisms of age macular degeneration (AMD), as well as the role of antioxidants (AOX) and omega-3 fatty acids ( ω -3) supplements in AMD prevention. Materials and Methods. Current knowledge on the cellular/molecular mechanisms of AMD and the epidemiologic/experimental studies on the effects of AOX and ω -3 were addressed all together with the scientific evidence and the personal opinion of professionals involved in the Retina Group of the OFTARED (Spain). Results. High dietary intakes of ω -3 and macular pigments lutein/zeaxanthin are associated with lower risk of prevalence and incidence in AMD. The Age-Related Eye Disease study (AREDS) showed a beneficial effect of high doses of vitamins C, E, beta-carotene, and zinc/copper in reducing the rate of progression to advanced AMD in patients with intermediate AMD or with one-sided late AMD. The AREDS-2 study has shown that lutein and zeaxanthin may substitute beta-carotene because of its potential relationship with increased lung cancer incidence. Conclusion. Research has proved that elder people with poor diets, especially with low AOX and ω -3 micronutrients intake and subsequently having low plasmatic levels, are more prone to developing AMD. Micronutrient supplementation enhances antioxidant defense and healthy eyes and might prevent/retard/modify AMD.
Figures
Figure 1
Oxidative stress (OS) is widely accepted as a key player in the initiation and progression of ocular diseases, including AMD. The chain reactions of reactive oxygen species (ROS) include the anion superoxide (O2 •−), hydrogen peroxide (H2O2), and hydroxyl radical (•OH), all of them being able to importantly damage the cells through oxidation of lipids, proteins, and nucleic acids. These alterations lead to changes in protein function. Abbreviations: e: electron, SOD: superoxide dysmutase, and Fe: iron.
Figure 2
Molecules involved in angiogenesis. There are many molecules that mediate-regulate angiogenesis. The seven classes enclosed in the figure are (1) growth factors and its receptors, (2) transcription factors, (3) cell adhesion molecules, (4) signalling molecules, (5) extracellular matrix proteins, (6) proteinases, and (7) molecules involved in development and maturation. Several of these molecules have been considered for potential diagnosis or therapeutic approaches to control pathological angiogenesis.
Figure 3
ROS-mediated apoptosis. In order to transmit physiological ROS-mediated signals and to accommodate to the OS, the cells have a wide spectrum of intracellular signal transduction systems, including protein kinase cascades. Much of these pathways are engaged in the route to apoptosis, including MAP kinases/ASK1 upstream regulator, PKB/Akt-ERK. MKP/1 and glutamate-induced cell death. Abbreviations: Akt protein kinase B (PKB), a serine/threonine-specific protein kinase; ASK1 apoptosis signal-regulating kinase 1, ERK extracellular signal-regulated kinase, Glu glutamate, JNK c-Jun NH2-terminal kinase, MAPK mitogen-activated protein kinase, MKP-1 MAPK phosphatase-1, PI3-K phosphatidylinositol 3-kinase, PKA protein kinase A, PKB protein kinase B, PKC protein kinase C, PKD protein kinase D, ROK Rho kinase, and ROS reactive oxygen species.
Figure 4
Inflammation and immune response (IIR). The primary defense mechanism of the immune system needs the activation of different cell phenotypes and intercellular signals to orchestrate all actions. Among the cytokines, the interleukines (IL) IL-1 and IL-6 and the TNFa are inducers of the IIR through the regulation of the monocytes. Immunocompetent cells are essential for an adequate immune system function, such as the macrophages, neutrophils, fibroblasts, and endothelial cells.
Similar articles
- Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.
Age-Related Eye Disease Study 2 Research Group. Age-Related Eye Disease Study 2 Research Group. JAMA. 2013 May 15;309(19):2005-15. doi: 10.1001/jama.2013.4997. JAMA. 2013. PMID: 23644932 Clinical Trial. - Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28.
Chew EY, Clemons TE, Agrón E, Domalpally A, Keenan TDL, Vitale S, Weber C, Smith DC, Christen W; AREDS2 Research Group. Chew EY, et al. JAMA Ophthalmol. 2022 Jul 1;140(7):692-698. doi: 10.1001/jamaophthalmol.2022.1640. JAMA Ophthalmol. 2022. PMID: 35653117 Free PMC article. Clinical Trial. - Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.
Age-Related Eye Disease Study 2 (AREDS2) Research Group; Chew EY, Clemons TE, Sangiovanni JP, Danis RP, Ferris FL 3rd, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, Bressler SB, Fish GE, Hubbard GB, Klein ML, Chandra SR, Blodi BA, Domalpally A, Friberg T, Wong WT, Rosenfeld PJ, Agrón E, Toth CA, Bernstein PS, Sperduto RD. Age-Related Eye Disease Study 2 (AREDS2) Research Group, et al. JAMA Ophthalmol. 2014 Feb;132(2):142-9. doi: 10.1001/jamaophthalmol.2013.7376. JAMA Ophthalmol. 2014. PMID: 24310343 Free PMC article. Clinical Trial. - Nutritional supplements for age-related macular degeneration.
Krishnadev N, Meleth AD, Chew EY. Krishnadev N, et al. Curr Opin Ophthalmol. 2010 May;21(3):184-9. doi: 10.1097/ICU.0b013e32833866ee. Curr Opin Ophthalmol. 2010. PMID: 20216418 Free PMC article. Review. - Lifestyle modification, nutritional and vitamins supplements for age-related macular degeneration.
Sin HP, Liu DT, Lam DS. Sin HP, et al. Acta Ophthalmol. 2013 Feb;91(1):6-11. doi: 10.1111/j.1755-3768.2011.02357.x. Epub 2012 Jan 23. Acta Ophthalmol. 2013. PMID: 22268800 Review.
Cited by
- Effects of Lutein on Hyperosmoticity-Induced Upregulation of IL-6 in Cultured Corneal Epithelial Cells and Its Relevant Signal Pathways.
Chao SC, Nien CW, Iacob C, Hu DN, Huang SC, Lin HY. Chao SC, et al. J Ophthalmol. 2016;2016:8341439. doi: 10.1155/2016/8341439. Epub 2016 Mar 7. J Ophthalmol. 2016. PMID: 27047687 Free PMC article. - Review of clinical approaches in fluorescence lifetime imaging ophthalmoscopy.
Sauer L, Andersen KM, Dysli C, Zinkernagel MS, Bernstein PS, Hammer M. Sauer L, et al. J Biomed Opt. 2018 Sep;23(9):1-20. doi: 10.1117/1.JBO.23.9.091415. J Biomed Opt. 2018. PMID: 30182580 Free PMC article. Review. - Efficacy of a Fatty Acids Dietary Supplement in a Polyethylene Glycol-Induced Mouse Model of Retinal Degeneration.
Cammalleri M, Dal Monte M, Locri F, Lardner E, Kvanta A, Rusciano D, André H, Bagnoli P. Cammalleri M, et al. Nutrients. 2017 Sep 29;9(10):1079. doi: 10.3390/nu9101079. Nutrients. 2017. PMID: 28961167 Free PMC article. - Ginkgo Biloba Extract in Ophthalmic and Systemic Disease, With a Focus on Normal-Tension Glaucoma.
Labkovich M, Jacobs EB, Bhargava S, Pasquale LR, Ritch R. Labkovich M, et al. Asia Pac J Ophthalmol (Phila). 2020 May-Jun;9(3):215-225. doi: 10.1097/APO.0000000000000279. Asia Pac J Ophthalmol (Phila). 2020. PMID: 32282348 Free PMC article. Review. - Novel lutein loaded lipid nanoparticles on porcine corneal distribution.
Liu CH, Chiu HC, Wu WC, Sahoo SL, Hsu CY. Liu CH, et al. J Ophthalmol. 2014;2014:304694. doi: 10.1155/2014/304694. Epub 2014 Jul 2. J Ophthalmol. 2014. PMID: 25101172 Free PMC article.
References
- Soubrane G, Cruess A, Lotery A, et al. Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. Archives of Ophthalmology. 2007;125(9):1249–1254. - PubMed
- Miller JW. Age-related macular degeneration revisited—piecing the puzzle: the LXIX Edward Jackson memorial lecture. The American Journal of Ophthalmology. 2013;155:1–35. - PubMed
- Aslam T, Delcourt C, Silva R, et al. Micronutrients in age-related macular degeneration. Ophthalmologica. 2012;229:75–79. - PubMed